thiotepa riemser
esteve pharmaceuticals gmbh - tiotepa - hematopoietic stem cell transplantation; neoplasms - antineoplastiske midler - thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients. thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients.
trica 20 mg/ ml
esteve pharmaceuticals gmbh - triamcinolonheksacetonid - injeksjonsvæske, suspensjon - 20 mg/ ml
akynzeo 300 mg / 0.5 mg
orifarm as - netupitant / palonosetron - kapsel, hard - 300 mg / 0.5 mg
ismo retard 40 mg
2care4 - isosorbidmononitrat - depottablett - 40 mg
clopidogrel acino pharma gmbh
acino pharma gmbh - klopidogrel - peripheral vascular diseases; stroke; myocardial infarction - antithrombotic agents - clopidogrel er angitt i voksne for forebygging av atherothrombotic hendelser i:pasienter som lider av hjerteinfarkt (fra noen få dager til mindre enn 35 dager), ischaemic slag (fra 7 dager til mindre enn 6 måneder) eller etablert perifer arteriell sykdom. for ytterligere informasjon, vennligst referer til seksjon 5.
clopidogrel acino pharma
acino pharma gmbh - klopidogrel - peripheral vascular diseases; stroke; myocardial infarction - antithrombotic agents - clopidogrel er angitt i voksne for forebygging av atherothrombotic hendelser i:pasienter som lider av hjerteinfarkt (fra noen få dager til mindre enn 35 dager), ischaemic slag (fra 7 dager til mindre enn 6 måneder) eller etablert perifer arteriell sykdom. for ytterligere informasjon, vennligst referer til seksjon 5.
laktulose mip pharma 650 mg/ ml
mip pharma gmbh - laktulose - mikstur, oppløsning - 650 mg/ ml
rivastigmine 1 a pharma
1 a pharma gmbh - rivastigmin - alzheimer disease; dementia; parkinson disease - psychoanaleptics, - symptomatisk behandling av mild til moderat alvorlig alzheimers demens. symptomatisk behandling av mild til moderat alvorlig demens hos pasienter med parkinsons sykdom.
sapropterin dipharma
dipharma arzneimittel gmbh - sapropterin dihydrochloride - phenylketonurias - andre alimentary tract and metabolism products, - sapropterin dipharma is indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with phenylketonuria (pku) who have been shown to be responsive to such treatment. sapropterin dipharma is also indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with tetrahydrobiopterin (bh4) deficiency who have been shown to be responsive to such treatment.
pregabalin sandoz gmbh
sandoz gmbh - pregabalin - anxiety disorders; epilepsy - antiepileptics, - epilepsypregabalin sandoz gmbh er indisert som tilleggsbehandling hos voksne med partielle anfall med eller uten sekundær generalisering. generell angst disorderpregabalin sandoz gmbh er angitt for behandling av generalisert angstlidelse (gad) i voksne.